1. Home
  2. BOLD

as 04-18-2025 1:32pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Nasdaq

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Founded: 2018 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 30.3M IPO Year: 2024
Target Price: $22.50 AVG Volume (30 days): 69.6K
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.85 EPS Growth: N/A
52 Week Low/High: $1.06 - $12.65 Next Earning Date: 05-12-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: